Vera Therapeutics, Inc.
VERAHealthcareNASDAQBiotechnology · Last scanned Jun 3, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Vera Therapeutics, Inc. focuses on Biotechnology services and products. Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company carries a $2.24B market cap, placing it firmly in the mid-cap category. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Market Cap
$2.24B
Beta
0.95
P/E (TTM)
—
P/E (Fwd)
-8.22
EPS (TTM)
$-5.54
EPS (Fwd)
$-3.80
ROE
-71.3%
ROA
-38.9%
Cash
$596.8M
Total Debt
$76.9M
Free CF
-$179.4M
52W Change
-2.3%
Annual Financials
Cash vs Debt
With $596.8M in cash and $76.9M in debt, VERA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$179.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -71.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing VERA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.